RoslinCT Wins Manufacturer of the Year at the 9th Massachusetts Manufacturing Awards Ceremony
HOPKINTON, Mass., Oct. 02, 2024 – RoslinCT, a leading provider of cell and gene therapy manufacturing services, today announced that it has been recognized as Manufacturer of the Year by the Commonwealth of Massachusetts at the 9th Annual Manufacturing Awards. RoslinCT was honored for its exceptional contributions to the state’s biotechnology and life sciences sector, receiving the award at the prestigious ceremony held at Gillette Stadium.
The award highlights RoslinCT’s leadership in advanced cell therapy manufacturing, including its work with cutting-edge technologies such as CRISPR-edited therapies and induced pluripotent stem cells (iPSCs). With purpose-built cGMP manufacturing suites in both Hopkinton, Massachusetts, and Edinburgh, Scotland, RoslinCT has established itself as a global leader supporting the partners in the development and commercialization of innovative therapies.
“We are extremely proud to receive this recognition from the Commonwealth of Massachusetts”, said Garry Menzel, President of RoslinCT. “Our team is dedicated to advancing the development of transformative cell and gene therapies through excellence in manufacturing and innovation. This award reflects the incredible work our teams are doing to push the boundaries of what’s possible in this field.”
Dean Morris, COO of RoslinCT US added, “This honor showcases the strength of our Hopkinton facility and the strategic investments we’ve made to deliver high-quality cell therapy products. As we continue to expand and automate our operations, we are committed to driving efficiency and supporting the needs of our clients and their patients.”
RoslinCT’s recognition at the Massachusetts Manufacturing Awards is a testament to its commitment to innovation and quality in the biotech manufacturing space. As part of its long-term vision, the company plans to further expand its capacity and adopt advanced technologies to enhance the efficiency and scalability of its operations.
The Massachusetts Manufacturing Awards, hosted by the Legislative Manufacturing Caucus, celebrates companies that have demonstrated leadership and excellence in manufacturing across the Commonwealth. The caucus works to foster innovation, support workforce development, and advance strategic investments in the manufacturing sector, recognizing the critical role that companies like RoslinCT play in the state’s economic growth and development.
ENDS
About RoslinCT
About RoslinCT
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialization.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is a GHO Capital portfolio company.
Discover more about our services at www.roslinct.com.
